Back to Explorer

Hysteroscopic and Laparoscopic Insufflators: Submission Guidance for a 510(k)

FinalCenter for Devices and Radiological Health07/31/1995

Description

This guidance was written prior to the February 27, 1997 implementation of FDA’s Good Guidance Practices, GGP’s. It does not create or confer rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. This guidance will be updated in the next revision to include the standard elements of GGP’s.

Scope & Applicability

Product Classes

3
Intravascular Administration Sets

Subject of the guidance document for premarket notification submissions.; Subject of the premarket notification guidance

Class II

The devices that are the subject of this guidance are Class II non-spinal metallic bone screws and washers

Intravascular Administration Set

The primary device type covered by the guidance; device used to administer fluids from a container to a patient's vascular system

Stakeholders

1
manufacturer

Entity required to conduct postmarket surveillance; entity responsible for submitting postmarket surveillance plans; Entity holding the approved PMA, HDE, or cleared 510(k); The entity responsible for conducting postmarket surveillance and submitting reports.; Entity that can use the checklist as a reference for submissions.

Regulatory Context

Attributes

3
Indications for use

Guidance discusses LOINC codes for uncleared or unapproved indications.

SAL

Sterility Assurance Level

Sterility Assurance Level

Quality parameter that must remain unchanged for the policy

Identified Hazards

Hazards

6
Adverse tissue reaction

Risk management information should identify hazardous situations such as adverse tissue reaction.

Unrestricted flow

Warning required for infusion pumps with no restricted flow feature

Improper use

Identified risk associated with sharps injury prevention features

Infection

Risk to human health from failure to assure sterility

MRI environment

Safety risk associated with metallic components

Device malfunction

Identified risk associated with sharps injury prevention features

Related CFR Sections (5)

Related Warning Letters (10)

  • CGMP/QSR/Medical Devices/Adulterated

    Envoy Medical Inc.

    2025-12-09
  • CGMP/QSR/Medical Devices/Adulterated

    Hong Qiangxing Shenzhen Electronics Limited

    2025-11-25
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

    SeniorLife Technologies, Inc.

    2025-09-16
  • CGMP/QSR/Medical Devices/Adulterated

    Spectra Therapy, LLC

    2025-08-12
  • CGMP/QSR/Medical Devices/Adulterated

    Mectronic Medicale S.R.L.

    2025-08-05
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

    WHOOP, Inc.

    2025-07-15
  • CGMP/QSR/Medical Devices/Adulterated

    Aju Pharm Co., Ltd.

    2025-06-24
  • CGMP/QSR/Medical Devices/Adulterated

    Sedecal S.A.

    2025-05-27
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

    DRG Instruments GmbH

    2025-05-27
  • CGMP/QSR/Medical Devices/Adulterated

    NeuroSync, Inc.

    2025-05-20

See Also (8)